Capricor Therapeutics, Inc. (CAPR) - Stock Analysis
Last updated: Mar 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEâ3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEâ3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk).
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Persistent losses ⢠Cash burn CAPR has a resilient balance sheet with strong liquidity and sizable invested assets but is undermined by sustained operating losses, cash burn, and absent recent revenue, driving a sharply lower market valuation.
Price Behavior
Key Price Behavior Insights: ⢠Short-term uptrend ⢠Defended support ⢠Approaching resistance Support Level: $25â$26 Resistance Level: $28â$29 CAPR is in a short-term uptrend, trading above its last month simple moving average after roughly a 21% gain over the last month, with defended support near $25â$26 but facing resistance around $28â$29 and elevated short-term volatility from a sharp midâmonth dip and quick rebound.
Sentiment & News
Key News Insights: ⢠New institutional stake ⢠215,675 shares ⢠No operational details GSA Capital opened a new $1.56M position in Capricor Therapeutics (215,675 shares) in Q3, indicating fresh institutional interest though no operational or timing details were disclosed.
AI Summary
CAPR has shifted from a speculative R&D bet to a nearâterm regulatory/commercial binaryâHOPEâ3 efficacy and resolved CMC make FDA approval and an ~$80M milestone plausible, so take a targeted, eventâdriven position ahead of the resubmission while actively monitoring Cohort B GMP execution and cash runway into 2026 to avoid dilution if approval delays occur.
Description
Capricor Therapeutics is a clinical-stage biotechnology company developing cell- and exosome-based therapies for a range of diseases. Its lead candidate, CAP-1002, has completed a Phase III trial in late-stage Duchenne muscular dystrophy and is in Phase II testing for SARSâCoVâ2ârelated cytokine storm; the pipeline also includes a preclinical program for trauma-related injuries and vaccine candidates targeting COVIDâ19. The company outsources clinical manufacturing of CAP-1002 to Lonza Houston, was founded in 2005, and is based in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | CAPR | Capricor Therapeutics, Inc. | High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEâ3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEâ3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk). | Active | -8.7% |